DIR6 Antibody

DR6 Antibody Characteristics

DR6 antibodies exhibit distinct properties across clones and applications:

Key features include:

• Epitope targeting: Most bind the extracellular cysteine-rich domain (CRD1)

• Signaling activation: Agonist clones like DQM3 induce TRADD-mediated JNK/NF-κB pathways

• Cross-reactivity: Limited to human/mouse/rat models in 83% of commercial antibodies

Apoptotic Regulation

DR6 activation triggers caspase-dependent apoptosis through:

1. TRADD/FADD complex recruitment

2. Mitochondrial cytochrome c release

3. BAX protein activation

Notably, β-amyloid precursor protein (APP) cleavage generates N-APP fragments that bind DR6, inducing neuronal degeneration .

Immune Modulation

DR6 regulates adaptive immunity by:

• Inhibiting Th2 cytokine production (IL4, IL5, IL10)

• Reducing antigen-induced IgM/IgG synthesis

• Modulating T-cell differentiation via JNK suppression

Western Blot Performance

• ab8417 : Detects 68 kDa band in K562/Raji lysates (predicted 72 kDa)

• 93026 : Identifies endogenous DR6 at 80 kDa and 120 kDa isoforms

Functional Assays

Agonist antibody DQM3 demonstrates:

• 3.8-fold increase in TRADD binding (p<0.01)

• Dose-dependent JNK phosphorylation (EC50=12.5 nM)

Key Applications

• Alzheimer's disease models (APP-DR6 axis)

• Autoimmunity studies (Th2 regulation)

• Cancer immunotherapy development

Unresolved Questions

• Endogenous ligand identity remains unknown

• Structural basis for isoform-specific signaling (80 vs 120 kDa)

• InvD gene contributions to DR6 antibody diversity